Clinical evaluation of intrapericardial pneumonectomies applied in non-small cell lung cancer

Lung Cancer Staging and the Home Insurance Building Constructed in 1884–1885

Adjuvant chemotherapy for surgically resected non–small cell lung cancer

Objective To test the expression of phosphoinositide- 3- kinase, regulatory subunit 3 (PIK3R3)in the human non- small cell lung cancer(NSCLC) tissues, and to observe the effect of PIK3R3 on the epithelial- mesenchymal transition(EMT)and migration of NSCLC cell lines A549 and PC- 9. Methods Total RNA and total protein lysate from the NSCLC tissues and paratumor tissues of 22 or 7 patients with NSCLC were prepared respectively,and the expression of PIK3R3 was tested by real- time quantitative polymerase chain reaction(Real- time PCR)and Western blotting;PIK3R3 was overexpressed or down- regulated by lentivirus infection, then the effect of PIK3R3 on the migration was detected by Transwell assay, and the expression of EMT related proteins were detected by Western blotting,and the binding of snail family zinc finger(SNAI)1 and SNAI2 on the promoter of cadherin 1(CDH1)were measured by chromatin immunoprecipitation assay(ChIP),and the transcription activity of CDH1 was detected by luciferase reporter assay. Results The expression of PIK3R3 was elevated in NSCLC patients'tumor tissues compared with the paratumor tissues; The migration of A549 and PC- 9 cells was enhanced after PIK3R3 overexpression(A549 Control:46±3, PIK3R3:92±5; PC- 9 Control:25±2, PIK3R3:53±3), with the expression of CDH1 depressed and elevation of VIM, SNAI1 and SNAI2, which were related to the progress of EMT; The binding activity of SNAI1 and SNAI2 on the CDH1 promoter was elevated 9 times and 3.8 times, respectively, and the transcriptive activity of CDH1 was depressed to 30%.To the opposite, the migration of A549 and PC- 9 cells were inhibited after PIK3R3 down- regulated(A549 sh- Control:58±5,sh- PIK3R3:13±3; PC- 9 sh- Control:28±5,sh- PIK3R3:10±3), with the expression of CDH1 elevation and depressed of VIM, SNAI1 and SNAI2.The binding activity of SNAI1 and SNAI2 on the CDH1 promoter was reduced, and the transcriptive activity of CDH1 was increased 3.6 times. Conclusion The expression of PIK3R3 was elevated in NSCLC,and overexpression of PIK3R3 could induce the EMT and migration of A549 and PC- 9 cells;on the contrary, down- regulation of PIK3R3 could inhibit the EMT and migration of A549 and PC- 9 cells. Key words: Phosphoinositide-3-kinase; Regulatory subunit 3; Non-small cell lung cancer; Migration; Epithelial-mesenchymal transition

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Background: Lung cancer is the most common cause of cancer death among men and women in the United States, with 85% of all cases characterized as non-small cell lung cancer (NSCLC). These cancers are often diagnosed at advanced stage due to inapparent clinical symptoms. In 2015, the Food and Drug Administration approved the first use of immunotherapy for NSCLC, and it has since become a standard modality for treatment among advanced-stage NSCLC patients. Although significant racial disparities have been documented in overall NSCLC survival, it is unclear whether these disparities persist upon equal utilization of immunotherapy. The purpose of this study was to evaluate the association between race and all-cause mortality among advanced-stage non-small cell lung (NSCLC) cancer patients who received immunotherapy. Methods: We obtained data from the 2016 National Cancer Database on patients diagnosed with advanced-stage (III-IV) NSCLC from 2015-2016. The NCDB is a joint project of the American Cancer Society and the Commission on Cancer of the American College of Surgeons, and captures 70% of all patients with newly diagnosed cancer in the United States. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) by race/ethnicity. Additionally, we evaluated the interaction of race/ethnicity with Charlson-Deyo comorbidity score and area-level median income using stratified models and formal tests of interaction. Results: A total of 3,068 patients were included. NH-Black patients had a lower risk of death relative to NH-White patients (HR 0.85; 95% CI 0.74, 0.98) after adjusting for sociodemographic, clinical, and treatment factors. Formal tests of interaction evaluating race with Charlson-Deyo comorbidity score and race with area-level median income were nonsignificant. However, in stratified analyses, NH-Black vs. NH-White patients had a lower risk of death in models adjusted for sociodemographic factors among those with at least one comorbidity (HR 0.76; 95% CI 0.59, 0.98), and those living in regions within the two lowest quartiles of median income (HR 0.82; 95% CI 0.69, 0.98). Conclusions: Among advanced-stage NSCLC patients who received immunotherapy, NH-Black patients experienced higher survival compared to NH-White patients. We urge the implementation of policies and interventions that seek to equalize access to care as a means of addressing differences in overall NSCLC survival by race. Citation Format: Anjali Gupta, Tomi Akinyemiju. Racial differences in survival among advanced-stage non-small cell lung cancer patients who received immunotherapy: An analysis of the U.S. National Cancer Database (NCDB) [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-107.

Objective To observe the clinical efficacy and adverse effects of combination chemotherapy with docetaxel com- bined cisplafin in the treatment of Ⅲ～Ⅳ stage non small - cell lung cancer (NSCLC). Methods Thirty - two patients with Ⅲ- Ⅳ stage NSCLC were enrolled into this study and given treatment of docetaxel combined eisplatin 35 mg/m2 of docctaxel was injec- ted within one hour in the first and eighth day combined with injection of 25 mg/m2 cisplatin in first 3 days. 3 mg of granisetron were injected to prevent vomiting before combination chemotherapy. At least 2 courses were conducted with an interval of 28 days. Imageological examination was done and the diameters of tumor were measured to evaluate the effect of treatment and adverse effects. Results The total responsive rate was 40.63% (13/32), 2 of which were cure recovery(CR) and 11 were partial recovery (PR). Responsive rate was 45.80% (11/24) in patients with Ⅲ stage NSCLC and 25.00% (2/8) in patients with Ⅳ stage NSCLG respectively. The median survival time was 7.5 months. The one year survive rate was 65.63%. The main adverse effect was bone marrow depression. Conclusion Combination chemotherapy with docetaxel combined cisplatin in the treatment of Ⅲ- Ⅳ stage NSCLC has good clinical efficacy, light adverse effects and better tolerance, may be an effective and safe treatment for NSCLC. Key words: Docetaxel; Cisplatin; Combination chemotherapy; Non small -cell lung cancer

Objective To explore the association of Leptin gene-2 548 G/A polymorphism with the susceptibility and prognosis of non- small cell lung cancer(NSCLC). Methods A total of 162 patients with NSCLC and 200 controls were enrolled in the case-control study. The genotypes were detected using reaction-restriction fragment length polymorphism(PCR-RFLP). Relevant clinicopathological data of selected cases were collected and analyzed. Results The frequencies of AA, GA and A allele in cases(AA:35.2%;GA:46.3%;A:58.3%)were higher than that in controls(AA:16.5%;GA:40.0%;A:41.7%),and significant differences were revealed[odds ratio (OR)= 5.009,95% confidence interval(CI):2.758- 9.097,P< 0.01;OR= 2.719, 95% CI:1.615 - 4.578, P< 0.01;OR= 2.436, 95% CI:1.804- 3.289, P< 0.01], respectively. The frequencies of AA+ GA genotype(58.3%) was found higher than GG genotype(33.3%)in NSCLC inⅢ+ IV stage, likewise, the frequencies of AA+ GA genotype(62.1%) were also found higher than GG genotype(40.0%) in NSCLC with lymph node metastasis, significant differences were also showed (both P< 0.05), and the survival of individuals carrying GA+ AA(37.7±1.1) genotype was markedly reduced compared to that carrying GG(45.9±2.9)genotype(χ2= 8.215,P< 0.01). Conclusion The present study suggests that the Leptin gene-2 548 G/A polymorphism may be associated with the susceptibility to NSCLC, and appear to jointly contribute to predicting a poor prognosis. Key words: Non-small cell lung cancer; Leptin; Polymorphism

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

Molecular Biologic Staging of Lung Cancer

Chemotherapy and Survival in Non-Small Cell Lung Cancer: The Old Vexata Questio

Lung Cancer

miR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1

Wise Choices to Improve the Quality of Lung Cancer Care.

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum of Its Parts